Regeneron beats first quarter estimates on Dupixent strength

Regeneron beat Q1 expectations with adjusted EPS of $9.47 versus $8.97 consensus and revenue of $3.6 billion versus $3.48 billion expected, helped by 33% growth in Dupixent global net sales to $4.9 billion and a 36% increase in Sanofi collaboration revenue to $1.6 billion. The offset was a 10% decline in combined U.S. EYLEA HD/EYLEA sales and lower GAAP gross margin of 76% versus 81% last year due to Limerick manufacturing disruption. Management cut full-year 2026 GAAP gross margin guidance to 77%-78% from 79%-80% and authorized a new $3.0 billion buyback after repurchasing $803 million in Q1.

Analysis

The core signal is not the headline beat, but the widening gap between a structurally high-multiple growth asset and a temporarily impaired cash generator. Dupixent continues to validate the Sanofi collaboration as a compounding earnings engine, which should keep REGN defended on pullbacks even if the market gives little credit for near-term pipeline optionality. The more important second-order effect is that management is effectively buying time: with buybacks still aggressive, the stock can absorb a margin reset as long as investors believe the manufacturing issue is contained to one quarter.

The real tension is in the mix shift. EYLEA HD is now doing the heavy lifting, but the legacy franchise remains a fading drag, so the market will increasingly price REGN on whether HD can fully offset competitive erosion faster than payer/channel pressure compresses ophthalmology economics. Margin recovery is the near-term catalyst, but also the near-term risk: if the Limerick disruption proves more persistent than guided, consensus 2026 gross margin assumptions will need another reset, which would hit a name that trades on quality and consistency rather than cheapness.

On the other side, SNY benefits less from the print than the market may assume. Investors often extrapolate Dupixent momentum into a cleaner read-through for Sanofi, but the collaboration structure dilutes the direct equity upside, meaning REGN captures a larger share of the economic acceleration. The consensus may be underestimating how much capital return plus pipeline breadth can cushion any temporary margin noise, while overestimating how quickly the ophthalmology franchise can stabilize without more visible evidence of share retention.

This is a classic “good business, noisy quarter” setup. The move looks underdone if production normalizes by quarter-end and buybacks continue at this pace, but overdone if the market starts treating the margin downgrade as a one-off when it is actually a sign of manufacturing fragility. The tradeable window is the next 4-8 weeks, until investors get clearer evidence on restart quality and whether HD’s growth is enough to offset the legacy decline.

Key Decisions for Investors

• Long REGN on any post-earnings weakness over the next 1-2 weeks; risk/reward favors a re-rating if gross margin recovery is confirmed into the next update, with downside limited by ongoing buybacks.
• Buy REGN June/September call spreads rather than outright stock to express confidence in manufacturing normalization; this captures a 6-10% upside move while defining risk if margin recovery slips.
• Pair trade: long REGN / short SNY for 1-3 months if you want cleaner exposure to the collaboration economics; REGN has the higher marginal benefit from Dupixent growth, while SNY’s equity upside is more diluted.
• Avoid chasing the EYLEA HD story via fresh longs until there is evidence that legacy erosion has bottomed; if the decline rate stays near current levels, the market will keep discounting the ophthalmology franchise as a slow-burning drag.
• If REGN rallies quickly on the print, trim into strength and keep a residual core position for the buyback catalyst; the key risk is that investors front-run a full margin rebound before production fully normalizes.